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In the present study we describe the toxicity of weekly high-dose (70–85mgm
 2) cisplatin in 400 patients (203 men, 197 women;
median age 54 years) with advanced solid tumours treated in the period 1990–2001 who took part in phase I/II trials, investigating
the feasibility and efficacy of weekly cisplatin alone, or in combination with paclitaxel or etoposide. Cisplatin was administered in
250ml NaCl 3% over 3h, for six intended administrations. The mean number of administrations was 5.3 (range, 1–6 administrations).
Reasons not to complete six cycles were disease progression (7.5%), haematological toxicity (9%), nephrotoxicity (7%), ototoxicity
(2.5%), neurotoxicity (1%), gastrointestinal toxicity (1%), cardiovascular complications (0.5%) or a combination of reasons including
noncompliance and patient’s request (5.5%). Logistic regression analysis was used to evaluate baseline parameters for prognostic
value regarding toxicity. Leukopenia correlated with etoposide cotreatment, and thrombocytopenia with cisplatin dose and prior
(platinum-based) chemotherapy. Risk factors for nephrotoxicity were older age, female gender, smoking, hypoalbuminaemia and
paclitaxel coadministration. Neurotoxicity 4grade 1 (11% of patients) was associated with prior chemotherapy and paclitaxel
coadministration. Symptomatic hearing loss occurred in 15% with anaemia as the predisposing factor. We conclude that weekly high-
dose cisplatin administered in hypertonic saline is a feasible treatment regimen.
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CIS-Diamminedichloroplatinum (cisplatin) is a commonly used
cytotoxic agent with a broad spectrum of activity against solid
malignant tumours, including germ cell, ovarian, endometrial,
cervical, urothelial, head/neck and lung cancer. When cisplatin was
first approved for commercial use in 1978, the major toxicities
were severe nausea and vomiting and a high incidence of renal
dysfunction. Although these adverse effects are still of concern,
they can be significantly reduced by the use of 5HT3-receptor
antagonists and vigorous hydration (Pinzani et al, 1994). Admin-
istration of cisplatin in hypertonic saline may further alleviate
nephrotoxic side effects (Ozols et al, 1984). Protective measures
against nausea, vomiting and renal dysfunction have created the
opportunity to increase the (individual and cumulative) cisplatin
dose. With mild to moderate myelosuppression during conven-
tional 3- or 4-weekly therapy, neurotoxicity (Cersosimo, 1989) and
ototoxicity (Laurell and Jungnelius, 1990) have emerged as the
remaining major dose-limiting side effects.
The rationale for weekly administration of high-dose cisplatin is
based on the tumour biological principle that frequent adminis-
tration of chemotherapy in a high dose results in more effective
killing of cancer cells and potentially reduces the risk of developing
chemotherapy resistance. Furthermore, by shortening the treat-
ment interval, tumour cells have less time for regrowth between
treatment courses. Weekly administration of cisplatin has
extensively been studied at our institution in a range of prospective
clinical trials (Planting et al, 1993, 1994, 1995a, b, 1997a, b; van der
Burg et al, 1998; van den Bent et al, 1999, 2002).
In the present analysis, we have pooled data of 400 patients
treated with cisplatin at weekly doses of 70–85mgm
 2 for an
intended number of six administrations, with the goal of
describing in detail the toxicity of this weekly regimen and of
identifing predisposing factors for the development of side effects,
with an emphasis on nephrotoxicity, neurotoxicity and ototoxicity.
PATIENTS AND METHODS
Patient selection
Patients who had been treated with weekly high-dose cisplatin in
the period 1990–2001 were analysed. The majority of patients
participated in phase I/II clinical trials (Planting et al, 1993, 1994,
1995a, b, 1997a, b; van der Burg et al, 1998, 2002; van den Bent et al,
1999). All study protocols were approved by the Institutional
Ethics Board and all participating patients gave written informed
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lconsent. According to the inclusion criteria of the trials, patients
were required to have locally advanced or metastatic cancer with
no better treatment options than weekly cisplatin as a single agent
or in combination with either i.v. paclitaxel or oral etoposide. Age
had to be X18 years, WHO performance status 0–2, and life
expectancy more than 12 weeks with adequate haematopoietic,
renal and hepatic function at study entry. Based on favourable
treatment results (Planting et al, 1997b), patients with locally
advanced head/neck cancer could be offered treatment with weekly
cisplatin induction chemotherapy followed by radiotherapy out-
side study protocols.
Treatment
Cisplatin was administered at a dose of 70–85mgm
 2 on days 1, 8,
15, 22, 29 and 36 as a single agent, or at a dose of 70mgm
 2 on
days 1, 8, 15, 29, 36 and 43 in combination with oral etoposide or
i.v. paclitaxel. Cisplatin powder was dissolved in 250ml NaCl 3%
and administered by i.v. infusion over 3h. Patients received
prehydration with 1l normal saline or dextrose-saline and
posthydration with 3l normal saline or dextrose-saline supple-
mented with KCl (20mmoll
 1) and MgSO4 (2gl
 1). Antiemetic
prophylaxis consisted of a 5HT3 antagonist in combination with
dexamethasone. Diuretics were not administered routinely.
Dose intensity
Dose reductions were not allowed. Cisplatin single-agent treatment
was postponed 1 week for a maximum of 3 weeks if WBC
o2.5 10
9l
 1 and/or platelets o75 10
9l
 1. When used in
combination with etoposide, cisplatin administration was post-
poned in the case of WBC o2.5 10
9l
 1 and/or platelets
o75 10
9l
 1 on day 8 or day 36, WBC o1.5 10
9l
 1 and/or
platelets o50 10
9l
 1 on day 15 or day 43, and WBC
o3.0 10
9l
 1 and/or platelets o100 10
9l
 1 on day 29. With
the cisplatin/paclitaxel regimen, treatment was postponed if WBC
o1.0 10
9l
 1 and/or platelets o50 10
9l
 1 on days 8, 15, 36 or
43, and if on day 29 WBC o3.0 10
9l
 1 and/or platelets
o100 10
9l
 1. Cisplatin was discontinued if creatinine clearance
fell below 45mlmin
 1 or in case of neurotoxicity 4grade 2.
The planned dose intensity was calculated by dividing the
planned total dose of cisplatin (mgm
 2) by the planned duration
of treatment given in weeks (i.e. 6 weeks for cisplatin single agent
and 7 weeks for cisplatin in combination with etoposide or
paclitaxel). The achieved dose intensity was calculated by dividing
the total administered dose (mgm
 2) by the actual treatment
duration given in weeks. Patients who did not complete treatment
due to nontoxicity reasons (e.g. disease progression, noncompli-
ance) were not evaluated for achieved dose intensity.
Data collection and statistical analysis
Pretreatment and follow-up studies have been reported in detail
elsewhere (Planting et al, 1993, 1994, 1995a, b, 1997a, b; van der
Burg et al, 1998, 2002; van den Bent et al, 1999). Patients’ baseline
characteristics analysed included age, sex, length, weight, body-
surface area (BSA), blood pressure, smoking and drinking habits,
amount of weight loss, performance status, tumour type, prior
anticancer treatment, planned cisplatin dose and dose intensity,
and cytotoxic comedication (etoposide, paclitaxel or none).
Physical examination, laboratory tests and assessment of toxicity
were performed weekly during treatment. Laboratory tests
included haemoglobin, WBC, granulocytes, platelets, albumin,
bilirubin, alkaline phosphatase, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), lactate dehydrogenase (LDH),
sodium, potassium, calcium, magnesium, creatinine and creatinine
clearance measured by 24-h urine collection. In addition,
creatinine clearance was estimated using the Cockroft and Gault
equation. Toxicity was assessed according to the Common Toxicity
Criteria (CTC), version 1.0, National Cancer Institute (NCI), and,
for the present analysis, was evaluated after three administrations
of weekly cisplatin, after six administrations and 3 months after
completion of the weekly cisplatin regimen. Since audiograms were
not routinely performed, grade 1 ototoxicity was not reported.
Patients who went off treatment before the fifth administration of
cisplatin for reasons other than the evaluated toxicity were
excluded from analysis of that toxicity, in order to prevent
under-reporting of toxicity.
Logistic regression analysis was used in order to test baseline
parameters for their prognostic value regarding toxicity. Patients
with neurological symptoms or hearing impairment at baseline
were excluded from logistic regression analysis for neurotoxicity
and ototoxicity, respectively. In order to eliminate the influence of
baseline serum creatinine and creatinine clearance on renal
toxicity assessment, renal toxicity was defined as a X25% decline
in the estimated creatinine clearance from baseline. After
univariate analysis, all baseline parameters were presented to the
multivariate model that used a stepwise procedure starting with an
empty model and putting the most significant factor at that time
into the model. This process was repeated until the P-value of the
factor involved exceeded 0.025. This level of statistical significance
was chosen to reduce the risk of finding purely coincidental
associations in view of the large amount of factors analysed. P-
values were calculated using the Wald test. For each parameter
remaining in the multivariate model, an odds ratio (OR) with 95%
confidence interval (CI) for the development of toxicity was
calculated.
RESULTS
Patient characteristics
Patient characteristics are shown in Table 1. A total of 400 patients
(203 males, 197 females) who had been receiving a total of 2116
weekly cisplatin administrations were included in the study.
Predominant tumour types were head and neck cancer (39%) and
ovarian cancer (27%). Of the 92 patients with prior chemotherapy,
88 patients had recurrent ovarian cancer after one or more
platinum-based regimens (cisplatin pretreatment in 40 patients).
The planned cisplatin dose was 70mgm
 2 for 323 patients
(81%) and 80mgm
 2 for 70 patients (18%). Five patients received
75mgm
 2, and two received 85mgm
 2. Cisplatin was adminis-
tered as a single agent to 143 patients (36%); 196 patients (49%)
received cisplatin in combination with oral etoposide and 61 (15%)
with i.v. paclitaxel. A total of 263 patients (66%) received six
cisplatin administrations: 151 without any delay (38%), 64 with 1
week delay (16%), 39 with 2 weeks delay (10%), seven with 3 weeks
delay (2%), and two with 4 weeks delay (0.5%). From the patients
that received four (n¼30) or five (n¼59) administrations of
cisplatin, 55 had no treatment delay (14%), 18 had 1 week delay
(4.5%), 10 had 2 weeks delay (2.5%) and six had 3 weeks delay
(1.5%); from the patients that received one (n¼8), two (n¼5) or
three (n¼35) cisplatin administrations, 46 had no delay (11%)
and two had a 1-week treatment delay (0.5%). The mean number
of cisplatin administrations was 5.3, with a median total cisplatin
dose of 420mgm
 2 (range, 70–480mgm
 2; mean,
379786mgm
 2). The mean duration of treatment was 6.571.9
weeks (range, 1–11 weeks; median, 7 weeks). The median achieved
dose intensity was 60mgm
 2 week
 1 (range, 10–80mgm
 2
week
 1; mean, 55.7711.6mgm
 2 week
 1).
Toxicity incidences (scored as the worst CTC grade) are shown
in Table 2. Nausea and vomiting were prevalent but did not result
in dose reduction or cessation of treatment. Reasons not to
complete treatment were disease progression (30 patients, 7.5%),
haematological toxicity (37 patients, 9%), renal toxicity (29
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lpatients, 7%), ototoxicity (10 patients, 2.5%), neurotoxicity (four
patients, 1%), gastrointestinal toxicity (three patients, 1%),
cardiovascular complications (two patients, 0.5%), or combina-
tions of reasons including noncompliance and patient’s request (22
patients, 5.5%). In total, 12 patients (3%) died within 30 days after
the last administration of weekly cisplatin; nine of them had
rapidly progressive disease.
Haematological toxicity
In 37 patients (9%), weekly cisplatin treatment was discontinued
because of haematological toxicity, in the majority of them (21
patients) only after the fifth administration. Anaemia was a
common adverse event. During the evaluation period 202 patients
(51%) received one or more transfusions. The median number of
erythrocyte units transfused was two (range, 0–17). Grade 3–4
leucopenia was common, and associated with etoposide cotreat-
ment (OR¼2.2, P¼0.007). Although frequently observed, grade 4
neutropenia was generally brief (o7 days in 74%; o14 days in
94%) and uncomplicated. Febrile neutropenia occurred in only
1.5% of patients. Grade 3–4 thrombocytopenia was observed in
22% of patients who received at least three administrations of
weekly cisplatin; 19 patients (5%) received platelet transfusions.
Thrombocytopenia was associated with prior chemotherapy
(OR¼3.2, P¼0.006) and cisplatin dose (80mgm
 2 versus
70mgm
 2:O R ¼2.9, P¼0.009). Paclitaxel coadministration was
not associated with enhanced haematological toxicity (OR¼0.39,
P¼0.1 for anaemia; OR¼1.9, P¼0.08 for leucopenia; OR¼0.53,
P¼0.2 for neutropenia; OR¼0.55, P¼0.3 for thrombocytopenia).
Nephrotoxicity
At baseline, serum creatinine (mean7standard deviation) was
84714mmol l
 1 with an estimated creatinine clearance of
83722mlmin
 1. After three and six administrations of weekly
cisplatin, the serum creatinine was 93740 and 102729mmoll
 1
respectively with an estimated creatinine clearance of 77723 and
69723mlmin
 1 respectively. A X25% reduction in creatinine
clearance was observed in 116 patients (29%). In 164 patients
(41%) the serum creatinine rose above the upper limit of normal
(grade 1, 127 patients (32%); grade 2, 35 patients (9%); grade 3,
two patients (0.5%)). Electrolyte disorders were frequently ob-
served. Mean7standard deviation serum concentrations of mag-
nesium, calcium, sodium and potassium declined from respectively
0.8170.09mmoll
 1 (range, 0.51–1.33mmoll
 1), 2.3970.14mmoll
 1
(range, 1.92–3.03mmoll
 1), 13973.7mmoll
 1 (range, 128–149mmol
l
 1)a n d4 . 2 70.41mmoll
 1 (range, 2.8–5.5mmoll
 1)a tb a s e l i n et o
0.7070.13mmoll
 1 (range, 0.22–1.62mmoll
 1), 2.2670.15mmoll
 1
(range, 1.59–2.69mmoll
 1), 13574.3mmoll
 1 (range, 117–
146mmoll
 1) and 4.070.50mmoll
 1 (range, 2.5–5.2mmoll
 1)
after three administrations, and 0.6270.14mmoll
 1 (range,
0.23–1.16mmoll
 1), 2.2470.16mmoll
 1 (range, 1.53–2.69mmoll
 1),
13574.1mmoll
 1 (range, 122–146mmoll
 1)a n d4 . 0 70.56mmoll
 1
(range, 2.2–5.6mmoll
 1) after six administrations of weekly
cisplatin.
Results of the logistic regression analysis for nephrotoxicity are
shown in Table 3. In the univariate analysis, age, female sex, prior
cisplatin treatment, paclitaxel cotreatment and hypoalbuminaemia
were associated with nephrotoxicity (defined as a X25% decline of
the estimated creatinine clearance at any time during the
evaluation period). After adjustment for prior chemotherapy and
additional chemotherapeutical agents, age and hypoalbuminaemia
remained significant whereas smoking and elevated serum alkaline
phosphatase concentrations were introduced as additional risk
factors. The multivariate analysis selected age, female gender,
smoking, paclitaxel coadministration and hypoalbuminaemia as
independent risk factors. Paclitaxel cotreatment (OR¼4.0,
P¼0.001), hypoalbuminaemia (OR¼3.5, P¼0.006) and smoking
(OR¼2.5, P¼0.002) were strong predisposing factors for renal
toxicity in the multivariate model. There was a gradual increase in
renal toxicity with increasing age at an OR of 1.03year
 1
(P¼0.007). Patients younger than 48 years had a 26% risk for
renal toxicity, which increased to 35% for patients aged 48–62
years and 41% for patients 462 years. Compared with men,
women had a two-fold risk of renal toxicity (OR¼2.0, P¼0.02).
Neurotoxicity
Clinical data on neurotoxicity (according to CTC criteria) were
fully available for the period of weekly cisplatin treatment, but
Table 1 Patient characteristics (n=400)
No. of patients (%)
Sex
Male 203 51
Female 197 49
Age (years)
Median 54
Range 19–79
WHO performance status
0 157 39
1 206 51
23 4 9
Unknown 3 1
Tumour type
Head and neck cancer 155 39
Ovarian cancer 108 27
CUP 47 12
NSCLC 36 9
Mesothelioma 24 6
Glioma 18 4
Miscellaneous 12 3
Prior chemotherapy
None 308 77
Platinum-based 88 22
Nonplatinum-based 4 1
WHO=World Health Organization; CUP=Carcinoma with unknown primary;
NSCLC=nonsmall cell lung cancer.
Table 2 Toxicity (%) of weekly cisplatin in 400 patients (worst toxicity
per patient)
CTC grade
a 01234
Anaemia 1 34 44 20 1
Leucopenia 10 18 35 30 7
Neutropenia 10 9 25 32 24
Thrombocytopenia 27 34 17 14 8
Nausea 18 44 30 8 0
Vomiting 36 30 27 6 1
Nephrotoxicity 59 32 8 1 0
Hypomagnesaemia 33 52 9 5 1
Hyponatraemia 55 23 18 3 1
Hypokalaemia 81 13 5 1 0
Hypocalcaemia 53 40 5 1 1
Neurotoxicity 53 36 8 3 0
Ototoxicity
b 58 F 27 14 1
aCommon Toxicity Criteria, Version 1.0, National Cancer Institute.
bAudiometry was
not routinely performed: grade 0 ototoxicity should be interpreted as grade 0 or 1.
Toxicity analysis of weekly cisplatin chemotherapy
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lwere missing in 71 of our patients (18%) at 2–4 months post-
treatment. Furthermore, it is noteworthy that 43 ovarian cancer
patients treated with weekly cisplatin in combination with
paclitaxel (11% of the study population) received additional 3-
weekly treatment with cisplatin and/or paclitaxel immediately
following the weekly regimen. Neurotoxicity (mostly peripheral
sensory polyneuropathy) was observed in 188 patients (47%) and
was mild to moderate in most cases: 145 patients (36%) developed
grade 1 neurotoxicity, 33 patients (8%) grade 2, nine patients (2%)
grade 3, and one patient experienced grade 4 neurotoxicity.
After univariate analysis a large number of baseline parameters
were found to be related with the development of grade 2–4
neurotoxicity: female sex, tumour type (ovarian cancer), prior
chemotherapy, cisplatin dose, paclitaxel coadministration, non-
smoking and alcohol consumption p2 unitsday
 1 (Table 4). After
adjustment for prior chemotherapy and cytotoxic cotreatment,
none of the (other) risk factors remained significant. After
multivariate analysis, prior platinum-based chemotherapy (cispla-
tin or carboplatin) and coadministration of paclitaxel remained
independent prognostic indicators for neurotoxicity. The ORs were
8.3 for paclitaxel coadministration (P¼0.001), 3.9 for pretreat-
ment with cisplatin (P¼0.01), and 3.5 for pretreatment with
carboplatin (P¼0.01).
Ototoxicity
Ototoxicity was observed in 168 patients (42%): 110 patients (28%)
had CTC grade 2 (reversible tinnitus), 55 (14%) grade 3, and three
patients (1%) had grade 4 ototoxicity. Table 5 shows the results of
the logistic regression analysis for ototoxicity defined as sympto-
matic hearing loss (grade 3–4). Anaemia was the single baseline
parameter associated with ototoxicity (OR¼3.1, P¼0.001).
DISCUSSION
The present study reports the toxic side effects of weekly high-dose
cisplatin chemotherapy in 400 patients with locally advanced and/
or metastatic cancer. Given the median number of six adminis-
trations of weekly cisplatin, the median total dose of 420mgm
 2
and the median dose-intensity of 60mgm
 2 week
 1, it can be
concluded that a short intensive weekly cisplatin schedule is a
Table 3 Logistic regression analysis for nephrotoxicity
a
Unadjusted Adjusted
b
Baseline parameter Odds ratio (CI) P-value Odds ratio (CI) P-value
Univariate analysis
Age (year
 1) 1.03 (1.00–1.05) 0.027 1.03 (1.00–1.05) 0.028
Sex (female) 1.71 (1.09–2.70) 0.021 1.46 (0.84–2.57) 0.183
BSA (m
 2) 0.79 (0.24–2.61) 0.696 0.97 (0.28–3.41) 0.966
Performance status 41 1.01 (0.41–2.45) 0.987 0.88 (0.35–2.23) 0.794
Tumour type (ovarian cancer) 1.54 (0.89–2.66) 0.124 0.63 (0.17–2.29) 0.478
Prior carboplatin treatment 0.85 (0.42–1.71) 0.656
Prior cisplatin treatment 2.16 (1.06–4.39) 0.035
Cisplatin dose X80mgm
 2 1.16 (0.65–2.09) 0.610 2.07 (0.99–4.30) 0.052
Paclitaxel cotreatment 3.46 (1.80–6.66) o0.001
Etoposide cotreatment 1.11 (0.66–1.88) 0.687
Weight loss 45% 0.99 (0.61–1.62) 0.978 1.18 (0.70–1.99) 0.530
Smoking 1.21 (0.75–1.97) 0.436 1.80 (1.01–3.22) 0.046
Alcohol intake 42 units day
 1 1.25 (0.76–2.03) 0.370 1.77 (0.96–3.23) 0.066
Systolic blood pressure 4150mmHg 1.44 (0.82–2.52) 0.206 1.30 (0.72–2.34) 0.387
Diastolic blood pressure 490mmHg 0.68 (0.34–1.38) 0.287 0.70 (0.34–1.46) 0.347
Creatinine clearance o70mlmin
 1 1.24 (0.77–2.01) 0.378 1.04 (0.62–1.74) 0.876
Hyponatraemia (o135mmoll
 1) 0.99 (0.50–1.96) 0.968 1.17 (0.58–2.39) 0.657
Hypokalaemia (o4.0mmoll
 1) 1.36 (0.79–2.33) 0.271 1.33 (0.76–2.33) 0.319
Hypocalcaemia (o2.2mmoll
 1) 0.95 (0.39–2.29) 0.907 0.95 (0.38–2.36) 0.911
Hypomagnesaemia (o0.7mmoll
 1) 2.15 (0.80–5.79) 0.129 2.31 (0.82–6.51) 0.113
Anaemia (haemoglobin onormal) 0.95 (0.61–1.49) 0.826 1.11 (0.69–1.79) 0.665
Hypoalbuminaemia (o35gl
 1) 3.13 (1.36–7.22) 0.007 3.22 (1.36–7.61) 0.008
Alkaline phosphatase 4normal 1.85 (0.93–3.65) 0.078 2.42 (1.17–4.97) 0.016
AST 4normal 1.61 (0.65–3.99) 0.308 1.47 (0.57–3.83) 0.428
ALT 4normal 1.83 (0.91–3.67) 0.091 1.72 (0.83–3.58) 0.145
LDH 4normal 1.10 (0.64–1.89) 0.734 1.19 (0.66–2.16) 0.568
Independent risk factor Odds ratio (CI) P-value
Multivariate analysis
Paclitaxel co-treatment 4.01 (1.83–8.77) 0.001
Smoking 2.50 (1.39–4.51) 0.002
Hypoalbuminaemia 3.49 (1.44–8.45) 0.006
Age (year
 1) 1.03 (1.01–1.06) 0.007
Female gender 1.99 (1.09–3.63) 0.025
aNephrotoxicity defined as X25% decline in estimated creatinine clearance (Cockroft-Gault).
bAdjusted for prior chemotherapy and cytotoxic cotreatment (paclitaxel,
etoposide). CI=95% confidence interval; BSA=body-surface area; AST=aspartate aminotransferase; ALT=alanine aminotransferase; LDH=lactate dehydrogenase.
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lfeasible treatment option, even in combination with i.v. paclitaxel
or oral etoposide.
Haematological toxicity resulted in treatment discontinuation in
only 9% of patients (the majority of them only missing one
administration of weekly cisplatin). Anaemia, however, was
frequently observed, and 51% of the patients received erythrocyte
transfusions. Grade 3–4 neutropenia and thrombocytopenia were
present, but generally of brief duration and without serious
complications. It is noteworthy that paclitaxel cotreatment (in
contrast to etoposide coadministration) did not result in enhanced
haematological toxicity; this could be explained by a favourable
pharmacological interaction between cisplatin and cremophor EL
(the vehicle for i.v. paclitaxel administration). It is already known
that the sequence paclitaxel–cisplatin induces less profound
neutropenia than the alternate sequence, which was first ascribed
to lower paclitaxel clearance rates after cisplatin administration
(Rowinsky et al, 1991). In other studies, however, no pharmaco-
kinetic interaction between paclitaxel and cisplatin could be found
(Gelderblom et al, 2002), whereas in vitro drug accumulation
studies have demonstrated significant reduction of intracellular
cisplatin concentrations in leucocytes (but not in tumour cells) in
the presence of cremophor EL, which was not observed with
paclitaxel alone (de Vos et al, 1997). The infusion of cremophor EL
immediately before cisplatin administration ameliorated leucope-
nia, neutropenia and thrombocytopenia (Gelderblom et al, 2002),
which may be of potential interest for improvement of the
therapeutic index of weekly cisplatin treatment.
Renal toxicity was present and necessitated discontinuation of
weekly cisplatin treatment in 7% of patients. According to CTC
criteria, nephrotoxicity was observed in 42% of patients (serum
creatinine above the upper limit of the normal); the majority of
them (32%) experienced mild (grade 1) renal toxicity, whereas 5%
of the patients already had elevated serum creatinine concentra-
tions at baseline. The estimated creatinine clearance declined from
83722mlmin
 1 at baseline to 69723mlmin
 1 after six admin-
istrations of weekly cisplatin. In 116 patients (29%), creatinine
clearance decreased 25% or more; the median decrease in
creatinine clearance was 16%. This certainly does not exceed the
nephrotoxicity reported from conventional 3-weekly cisplatin
treatment, and confirms previous observations that haematologi-
cal, and not renal, toxicity is the major dose-limiting adverse event
of weekly high-dose cisplatin chemotherapy (Planting et al, 1993,
1997a, b). The administration of cisplatin in a solution with
hypertonic saline may have alleviated renal toxicity, thus allowing
dose-dense cisplatin treatment. In animal models it has been
shown that administration of cisplatin in a vehicle of hypertonic
saline remarkably reduced nephrotoxicity without loss of anti-
tumour activity (Litterst, 1981). The most likely explanation is that
Table 4 Logistic regression analysis for neurotoxicity
a
Unadjusted Adjusted
b
Baseline parameter Odds ratio (CI) P-value Odds ratio (CI) P-value
Univariate analysis
Age (year
 1) 1.03 (0.99–1.07) 0.129 1.02 (0.98–1.06) 0.286
Sex (female) 4.73 (2.01–11.2) o0.001 1.53 (0.50–4.65) 0.452
BSA (m
 2) 0.48 (0.07–3.12) 0.442 0.68 (0.06–7.41) 0.750
Performance status 41 1.42 (0.40–5.11) 0.589 1.23 (0.29–5.22) 0.780
Tumour type (ovarian cancer) 8.69 (3.19–23.6) o0.001 4.57 (0.63–33.2) 0.133
Prior carboplatin treatment 4.07 (1.71–9.68) 0.001
Prior cisplatin treatment 6.48 (2.63–16.0) o0.001
Cisplatin dose X80mgm
 2 0.13 (0.02–0.96) 0.045 0.37 (0.04–3.38) 0.375
Paclitaxel cotreatment 15.3 (4.89–47.9) o0.001
Etoposide cotreatment 2.12 (0.67–6.76) 0.203
Weight loss 45% 0.83 (0.39–1.80) 0.643 2.00 (0.79–5.06) 0.144
Smoking 0.23 (0.09–0.60) 0.003 0.46 (0.16–1.34) 0.153
Alcohol intake 42 units per day 0.27 (0.09–0.79) 0.017 0.42 (0.12–1.43) 0.167
Systolic blood pressure 4150mmHg 1.72 (0.78–3.79) 0.176 1.32 (0.52–3.34) 0.556
Diastolic blood pressure 490mmHg 0.35 (0.08–1.51) 0.160 0.35 (0.07–1.66) 0.186
Creatinine clearance o70mlmin
 1 1.72 (0.84–3.53) 0.140 1.07 (0.47–2.45) 0.872
Hyponatraemia (o135mmoll
 1) 0.39 (0.09–1.71) 0.214 0.72 (0.15–3.39) 0.678
Hypokalaemia (o3.5mmoll
 1) 0.63 (0.24–1.69) 0.361 0.56 (0.19–1.69) 0.303
Hypocalcaemia (o2.2mmoll
 1) 1.85 (0.59–5.82) 0.290 2.06 (0.58–7.34) 0.268
Hypomagnesaemia (o0.7mmolll
 1) 0.48 (0.06–3.77) 0.484 0.27 (0.03–2.53) 0.252
Anaemia (haemoglobin onormal) 1.09 (0.54–2.20) 0.801 1.84 (0.80–4.20) 0.149
Hypoalbuminaemia (o35gl
 1) 0.82 (0.18–3.69) 0.800 0.77 (0.15–3.96) 0.754
Alkaline phosphatase 4normal 0.43 (0.10–1.89) 0.266 0.89 (0.19–4.23) 0.885
AST 4normal 1.53 (0.42–5.52) 0.518 1.27 (0.29–5.53) 0.753
ALT 4normal 1.37 (0.50–3.79) 0.543 1.08 (0.34–3.47) 0.892
LDH 4normal 1.07 (0.46–2.47) 0.871 1.13 (0.43–2.98) 0.809
Independent risk factor Odds ratio (CI) P-value
Multivariate analysis
Paclitaxel coadministration 8.33 (2.43–28.5) 0.001
Prior cisplatin treatment 3.88 (1.38–10.9) 0.010
Prior carboplatin treatment 3.50 (1.29–9.48) 0.014
aNeurotoxicity defined as CTC grade 2–4.
bAdjusted for prior chemotherapy and cytotoxic cotreatment (paclitaxel, etoposide). CI=95% confidence interval; BSA=body-surface
area; AST=aspartate aminotransferase; ALT=alanine aminotransferase; LDH=lactate dehydrogenase.
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lchloride excess results in the decreased formation of highly
nephrotoxic hydrolysis products of cisplatin (Earhart et al, 1983;
Bajorin et al, 1986; Jones et al, 1991).
Several baseline parameters were identified as independent
prognostic indicators for renal toxicity. The incidence of
nephrotoxicity gradually increased with age (OR¼1.03year
 1).
Although increased age was a risk factor for nephrotoxicity, our
study also demonstrates that weekly cisplatin treatment is not
necessarily contraindicated in elderly patients. Women had a two-
fold increased risk for renal toxicity compared with men. The
reason for this gender difference is not known. In a previous study
(de Jongh et al, 2001), we found that unbound cisplatin clearance
was 15% higher in men than in women but age had no significant
influence on this clearance. Paclitaxel coadministration was
strongly related to the development of nephrotoxicity (OR¼4.0,
CI¼1.8–8.8). Although the mechanism of this association is not
clear, it is in concordance with a report of increased nephrotoxicity
with paclitaxel/cisplatin combination as compared to cisplatin
single-agent chemotherapy in a small group of patients with
gynaecologic cancers (Merouani et al, 1997). Smoking also was an
independent risk factor for cisplatin-induced nephrotoxicity in the
present study (OR¼2.5, CI¼1.4–4.5). To our knowledge, this has
not been reported in the literature, and the underlying pathophy-
siological mechanism remains a matter of speculation. It is known,
however, that cigarette smoking is associated with oxidative stress
(Maytin et al, 1999), which could possibly lead to enhanced
formation of nephrotoxic platinum metabolites. Although it
cannot be excluded that smoking was associated with nephrotoxi-
city through coexisting smoking-related cardiovascular disease,
other indicators for cardiovascular disease such as hypertension
and diminished baseline creatinine clearance were not identified as
risk factors for cisplatin-induced nephrotoxicity. Furthermore,
there was no association between nephrotoxicity and a history of
hypertension, cardiovascular disease or diabetes mellitus in 425
patients treated with conventional cisplatin chemotherapy (Stewart
et al, 1997). Another strong predisposing factor for renal toxicity
was hypoalbuminaemia. This has also been described for patients
receiving conventional cisplatin treatment (Stewart et al, 1997).
Various studies have demonstrated that cisplatin-induced ne-
phrotoxicity is related to the peak plasma concentration and/or the
area under the plasma concentration–time curve of nonprotein
bound cisplatin (Reece et al, 1987; Nagai et al, 1996; Nagai and
Ogata, 1997). It is postulated that low serum albumin concentra-
tions are associated with increased plasma concentrations of
unbound cisplatin, resulting in enhanced renal toxicity. It is
noteworthy that cisplatin dose (in the range 70–80mgm
 2) was
not associated with nephrotoxicity and that baseline creatinine
clearance did not predict for nephrotoxicity (defined as relative
Table 5 Logistic regression analysis for ototoxicity
a
Unadjusted Adjusted
b
Baseline parameter Odds ratio (CI) P-value Odds ratio (CI) P-value
Univariate analysis
Age (year
 1) 0.99 (0.97–1.02) 0.699 0.99 (0.96–1.02) 0.635
Sex (female) 1.18 (0.65–2.13) 0.595 1.06 (0.51–2.23) 0.871
BSA (m
 2) 0.25 (0.05–1.28) 0.097 0.31 (0.06–1.65) 0.169
Performance status 41 0.86 (0.24–3.03) 0.815 0.96 (0.27–3.44) 0.945
Tumour type (ovarian cancer) 1.27 (0.63–2.57) 0.501 2.18 (0.43–11.1) 0.347
Prior carboplatin treatment 1.33 (0.60–2.99) 0.484
Prior cisplatin treatment 0.74 (0.24–2.21) 0.584
Cisplatin dose X80mgm
 2 0.75 (0.32–1.76) 0.506 0.67 (0.25–1.80) 0.430
Paclitaxel cotreatment 1.81 (0.82–4.01) 0.141
Etoposide cotreatment 0.71 (0.36–1.41) 0.324
Weight loss 45% 1.34 (0.72–2.50) 0.354 1.54 (0.79–2.97) 0.203
Smoking 1.30 (0.67–2.53) 0.432 1.48 (0.69–3.16) 0.310
Alcohol intake 42 units per day 1.30 (0.69–2.44) 0.413 1.25 (0.59–2.67) 0.561
Systolic blood pressure 4150mmHg 0.65 (0.28–1.51) 0.314 0.66 (0.28–1.60) 0.361
Diastolic blood pressure 490mmHg 0.36 (0.11–1.20) 0.096 0.40 (0.12–1.36) 0.141
Creatinine clearance o70mlmin
 1 1.26 (0.67–2.38) 0.479 1.21 (0.62–2.33) 0.577
Hyponatraemia (o135mmoll
 1) 0.92 (0.36–2.31) 0.854 1.12 (0.43–2.89) 0.816
Hypokalaemia (o4.0mmoll
 1) 0.81 (0.37–1.76) 0.597 0.85 (0.39–1.87) 0.686
Hypocalcaemia (o2.2mmoll
 1) 0.82 (0.23–2.87) 0.754 0.93 (0.26–3.32) 0.909
Hypomagnesaemia (o0.7mmoll
 1) 1.08 (0.29–3.98) 0.913 0.81 (0.21–3.21) 0.765
Anaemia (haemoglobin onormal) 2.38 (1.25–4.53) 0.008 3.14 (1.57–6.27) 0.001
Hypoalbuminaemia (o35gl
 1) 1.96 (0.74–5.25) 0.178 2.38 (0.85–6.66) 0.099
Alkaline phosphatase 4normal 0.61 (0.21–1.79) 0.365 0.77 (0.25–2.35) 0.641
AST 4normal 1.34 (0.43–4.18) 0.616 1.36 (0.42–4.35) 0.606
ALT 4normal 1.31 (0.54–3.17) 0.551 1.41 (0.56–3.53) 0.466
LDH 4normal 1.26 (0.63–2.52) 0.508 1.74 (0.81–3.73) 0.159
Independent risk factor Odds ratio (CI) P-value
Multivariate analysis
Anaemia 3.14 (1.57–6.27) 0.001
aOtotoxicity defined as symptomatic hearing loss (CTCgrade 3–4).
bAdjusted for prior chemotherapy and cytotoxic cotreatment (paclitaxel, etoposide). CI=95% confidence
interval; AST=aspartate aminotransferase; ALT=alanine aminotransferase; LDH=lactate dehydrogenase.
Toxicity analysis of weekly cisplatin chemotherapy
FE de Jongh et al
1204
British Journal of Cancer (2003) 88(8), 1199–1206 & 2003 Cancer Research UK
C
l
i
n
i
c
a
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firming data on conventional cisplatin treatment (Lagrange et al,
1997).
Neurotoxicity was found to be acceptable with weekly cisplatin
chemotherapy. According to previous studies, neurotoxicity is
mainly related to cumulative cisplatin dose, and shortening of the
treatment interval does not necessarily lead to worsening of the
neurotoxic side effects (Cavaletti et al, 1992; Hilkens et al, 1994,
1995). Neurotoxicity was evaluated during and immediately
following the weekly cisplatin regimen. Since cisplatin-induced
neuropathy can worsen during the first months after cisplatin
treatment (Hilkens et al, 1994), it was also assessed 2–4 months
after the completion of the weekly cisplatin regimen. The worst
toxicity score was used for evaluation of neurotoxicity. Here,
several biases were met. First, data on neurotoxicity at 2–4 months
were not traceable in 71 patients (18%), which probably led to
some underestimation of neurotoxicity. On the other hand, 11% of
the total study population received additional paclitaxel and/or
cisplatin immediately following the weekly cisplatin regimen with
possible overestimation of neurotoxicity. Nevertheless, only four
patients (1%) did not complete treatment due to neurotoxicity.
CTC grade 2–4 neurotoxicity was observed in 11% of the patients.
A large number of baseline parameters were identified as
potential risk factors for cisplatin-induced neurotoxicity by
univariate logistic regression analysis (Table 4): female sex,
ovarian cancer, prior platinum-based chemotherapy, individual
cisplatin dose, nonsmoking and alcohol consumption o3 units
daily. After adjustment for prior chemotherapy and cotreatment
(paclitaxel, etoposide), all other baseline parameters were elimi-
nated as risk factors. In the multivariate model, paclitaxel
coadministration and prior cisplatin and/or carboplatin treatment
were identified as independent risk factors for grade 2–4
neurotoxicity. The found associations could be anticipated and
this unfortunately does not add much to our knowledge of
cisplatin-induced neuropathy. Both paclitaxel and cisplatin are
neurotoxic agents, and a combination of cisplatin with taxanes is
known to result in increased neurotoxicity (Connelly et al, 1996;
Hilkens et al, 1997). Furthermore, cisplatin-induced neurotoxicity
is mainly dependent on the cumulative cisplatin dose (Cavaletti
et al, 1992; Hilkens et al, 1994, 1995). However, despite an
increased risk of neurotoxicity in the platinum pretreated patients,
severe neurotoxicity necessitating treatment discontinuation rarely
occurred. This is in concordance with a previous study demon-
strating that patients with absent or mild signs of neuropathy
after prior treatment with cisplatin to a cumulative dose of
400–450mgm
 2 can be retreated with six cycles of cisplatin
50–70mgm
 2 weekly with only a minimal risk of significant
neurotoxicity, not different from that in carboplatin pretreated
patients (van den Bent et al, 2002).
Ototoxicity is another major side effect of cisplatin chemo-
therapy, and is probably caused by cisplatin-induced degeneration
of the hair cells of the cochlea. Previous studies have shown that
ototoxicity is related to both cumulative and individual cisplatin
dose (Reddel et al, 1982; Schaeffer et al, 1985; Laurell and
Jungnelius, 1990). In the present study, tinnitus occurred in 25% of
the patients, 15% had subjective, symptomatic hearing loss, and in
2.5% weekly cisplatin treatment was not completed due to
ototoxicity.
Anaemia was a predisposing factor for grade 3–4 ototoxicity
(OR¼3.1, CI¼1.6–6.3). The pathophysiological background of
this association is presently unknown. Others previously identified
anaemia as a risk factor for cisplatin-induced ototoxicity (Blakley
et al, 1994). They also found a relation with hypoalbuminaemia,
which was a borderline prognostic factor (OR¼2.4, CI¼0.9–6.7,
P¼0.1) in the present study on weekly cisplatin. It is noteworthy
that age, sex, performance status, creatinine clearance and
individual cisplatin dose (in the range 70–80mgm
 2) were not
associated with ototoxicity. Remarkably, in the present analysis,
performance status was not associated with any chemotherapy-
induced toxicity, but this is probably related to the selection of
patients with good performance status to treat with dose-dense
cisplatin chemotherapy.
An advantage of the weekly regimen is shortening of the
treatment period from 18–24 weeks with standard treatment (six
courses with intervals of 3–4 weeks) to 6–8 weeks with weekly
treatment using similar total cisplatin dose. On theoretical grounds
it can be expected that weekly cisplatin treatment enhances
antitumour activity. Indeed, weekly cisplatin in combination with
either etoposide or paclitaxel was highly active and well tolerated
in the patients with advanced ovarian cancer, and even in the case
of platinum-refractory disease (defined as platinum treatment-free
interval o4 months) the objective response rate was in the order
of 50% (van der Burg et al, 1998, 2002). This suggests that
platinum resistance is a relative phenomenon that could be
overcome by shortening the treatment interval and supports the
use of weekly platinum treatment in patients with relapsed ovarian
cancer. For other tumour types, however, the place of weekly
cisplatin treatment remains to be determined.
In conclusion, in a large cohort of patients, we have demon-
strated that weekly cisplatin at doses of 70–80mgm
 2 adminis-
tered in hypertonic saline is a feasible treatment option, even when
combined with oral etoposide or i.v. paclitaxel. Predisposing
factors for treatment-related toxicity differ from side effect to side
effect.
REFERENCES
Bajorin DF, Bosl GJ, Alcock NW, Niedzwiecki D, Gallina E, Shurgot B
(1986) Pharmacokinetics of cis-diamminedichloroplatinum(II) after
administration in hypertonic saline. Cancer Res 46: 5969–5972
Blakley BW, Gupta AK, Myers SF, Schwan S (1994) Risk factors for
ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 120: 541–
546
Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pitelli MR,
Tredici G (1992) Cisplatin-induced peripheral neurotoxicity is dependent
on total-dose intensity and single-dose intensity. Cancer 69: 203–207
Cersosimo RJ (1989) Cisplatin neurotoxicity. Cancer Treat Rev 16: 195–211
Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G,
Belinson J (1996) Paclitaxel delivered at a 3-hr infusion with cisplatin in
patients with gynecologic cancers: unexpected incidence of neurotoxi-
city. Gynecol Oncol 62: 166–168
de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJA, Planting AST,
Nooter K, Stoter G, Sparreboom A (2001) Body-surface area-based
dosing does not increase accuracy of predicting cisplatin exposure. J Clin
Oncol 19: 3733–3739
de Vos AI, Nooter K, Verweij J, Loos WJ, Brouwer E, de Bruijn P, Ruijgrok
EJ, van der Burg MEL, Stoter G, Sparreboom A (1997) Differential
modulation of cisplatin accumulation in leukocytes and tumor cell lines
by the paclitaxel vehicle Cremophor EL. Ann Oncol 8: 1145–1150
Earhart RH, Martin PA, Tutsch KD, Ertu ¨rk E, Wheeler RH, Bull FE (1983)
Improvement in the therapeutic index of cisplatin (NSC 119875) by
pharmacologically induced chloruresis in the rat. Cancer Res 43: 1187–
1194
Gelderblom H, Loos WJ, Verweij J, van der Burg MEL, de Jonge MJA,
Brouwer E, Nooter K, Stoter G, Sparreboom A (2002) Modulation of
cisplatin pharmacodynamics by Cremophor EL: experimental and
clinical studies. Eur J Cancer 38: 205–213
Hilkens PHE, Planting AST, van der Burg MEL, Moll JWB, van Putten WLJ,
Vecht CJ, van den Bent MJ (1994) Clinical course and risk factors of
Toxicity analysis of weekly cisplatin chemotherapy
FE de Jongh et al
1205
British Journal of Cancer (2003) 88(8), 1199–1206 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lneurotoxicity following cisplatin in an intensive dosing schedule. Eur J
Neurol 1: 45–50
Hilkens PHE, Pronk LC, Verweij J, Vecht CJ, van Putten WLJ, van den Bent
MJ (1997) Peripheral neuropathy induced by combination chemotherapy
of docetaxel and cisplatin. Br J Cancer 75: 417–422
Hilkens PHE, van der Burg MEL, Moll JWB, Planting AST, van Putten WLJ,
Vecht CJ, van den Bent MJ (1995) Neurotoxicity is not enhanced by
increased dose intensities of cisplatin administration. Eur J Cancer 31A:
678–681
Jones MM, Basinger MA, Beaty JA, Holscher MA (1991) The relative
nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]
2+, and the
hydrolysis product of cisplatin in the rat. Cancer Chemother Pharmacol
29: 29–32
Lagrange JL, Me ´decin B, Etienne MC, Pivot X, Cassuto-Viguier E, Renee ´ N,
Thyss A, Ferrero JM, Otto J, Franc¸ois E, Milano G (1997) Cisplatin
nephrotoxicity: a multivariate analysis of potential predisposing factors.
Pharmacother 17: 1246–1253
Laurell G, Jungnelius U (1990) High-dose cisplatin treatment: hearing loss
and plasma concentrations. Laryngoscope 100: 724–734
Litterst CL (1981) Alterations in the toxicity of cis-dichlorodiamminepla-
tinum-II and in tissue localization of platinum as a function of NaCl
concentration in the vehicle of administration. Toxicol Appl Pharmacol
61: 99–108
Maytin M, Leopold J, Loscalzo J (1999) Oxidant stress in the vasculature.
Curr Atheroscler Rep 1: 156–164
Merouani A, Davidson SA, Schrier RW (1997) Increased nephrotoxicity of
combination taxol and cisplatin chemotherapy in gynecologic cancers as
compared to cisplatin alone. Am J Nephrol 17: 53–58
Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T,
Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y (1996)
Relationship between pharmacokinetics of unchanged cisplatin and
nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
Cancer Chemother Pharmacol 39: 131–137
Nagai N, Ogata H (1997) Quantitative relationship between pharmacoki-
netics of unchanged cisplatin and nephrotoxicity in rats: importance of
area under the concentration – time curve (AUC) as the major
toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 40:
11–18
Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC (1984)
High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19–24
Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balme `s P (1994)
Cisplatin-induced renal toxicity and toxicity-modulating strategies: a
review. Cancer Chemother Pharmacol 35: 1–9
Planting AST, Kho GS, van der Burg MEL, Goey SH, Schellens JHM, van
den Bent MJ, van der Gaast A, de Boer-Dennert M, Stoter G, Verweij J
(1997a) A phase II study of weekly high-dose cisplatin combined with
oral etoposide in advanced non-small cell lung cancer. Cancer Chemother
Pharmacol 40: 347–352
Planting AST, de Mulder PHM, de Graeff A, Verweij J (1997b) Phase II
study of weekly high-dose cisplatin for six cycles in patients with locally
advanced squamous cell carcinoma of the head and neck. Eur J Cancer
33: 61–65
Planting AST, Schellens JHM, Goey SH, van der Burg MEL, de Boer-
Dennert M, Stoter G, Verweij J (1994) Weekly high-dose cisplatin in
malignant pleural mesothelioma. Ann Oncol 5: 373–374
Planting AST, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J
(1993) Phase I/II study of a short course of weekly cisplatin in patients
with advanced solid tumours. Br J Cancer 68: 789–792
Planting AST, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J
(1995a) Phase I study of weekly high-dose cisplatin combined with long
term oral etoposide in advanced solid tumors. Ann Oncol 6: 190–192
Planting AST, van der Burg MEL, Goey SH, Schellens JHM, van den Bent
MJ, de Boer-Dennert M, Stoter G, Verweij J (1995b) Phase II study of a
short course of weekly high-dose cisplatin combined with long term oral
etoposide in pleural mesothelioma. Ann Oncol 6: 613–615
Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall HN (1982)
Ototoxicity in patients receiving cisplatin: importance of dose and
method of drug administration. Cancer Treat Rep 66: 19–23
Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance
as a predictor of ultrafilterable platinum disposition in cancer patients
treated with cisplatin: relationship between peak ultrafilterable platinum
plasma levels and nephrotoxicity. J Clin Oncol 5: 304–309
Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere
AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR,
Hendricks CB, Donehower RC (1991) Sequences of taxol and cisplatin: a
phase I and pharmacologic study. J Clin Oncol 9: 1692–1703
Schaeffer SD, Post JD, Close LG, Wright CG (1985) Ototoxicity of low- and
moderate-dose cisplatin. Cancer 56: 1934–1939
Stewart DJ, Dulberg CS, Mikhael NZ, Redmond D, Montpetit VAJ, Goel R
(1997) Association of cisplatin nephrotoxicity with patient characteristics
and cisplatin administration methods. Cancer Chemother Pharmacol 40:
293–308
van den Bent MJ, Pronk L, Sillevis Smitt PA, Vecht CJ, Eskens FA, Verweij J
(1999) Phase II study of weekly dose-intensified cisplatin chemotherapy
with oral etoposide in recurrent glioma. J Neuro-oncol 44: 59–64
van den Bent MJ, van Putten WLJ, Hilkens PHE, de Wit R, van der Burg
MEL (2002) Retreatment with dose-dense weekly cisplatin after previous
cisplatin chemotherapy is not complicated by significant neuro-toxicity.
Eur J Cancer 38: 387–391
van der Burg MEL, de Wit R, Stoter G, Verweij J (1998) Phase I study of weekly
cisplatin and weekly or 4-weekly taxol: a highly active regimen in advanced
epithelial ovarian cancer. Proc Am Soc Clin Oncol 17: abstract 1370
van der Burg MEL, de Wit R, van Putten WLJ, Logmans A, Kruit WHJ,
Stoter G, Verweij J (2002) Weekly cisplatin and daily oral etoposide is
highly effective in platinum pretreated ovarian cancer. Br J Cancer 86:
19–25
Toxicity analysis of weekly cisplatin chemotherapy
FE de Jongh et al
1206
British Journal of Cancer (2003) 88(8), 1199–1206 & 2003 Cancer Research UK
C
l
i
n
i
c
a
l